Actively Recruiting
Evaluating Trimodulin as Additional Treatment for Severe Community-acquired Pneumonia in Hospitalized Adults Using Mechanical Ventilation
Led by Biotest · Updated on 2026-09-14
590
Participants Needed
170
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.
CONDITIONS
Brief Title
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
Research Team
P
Patrick Langohr
C
Claudia Schulte
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here